Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
Twenty male hyperuricaemic patients with normal kidney function were studied and it was found that the serum concentrations and excretions rates in the 24-hour urine of allopurinol and oxipurinol do not differ significantly after 9 days of oral treatment with either 300 mg allopurinol or a combination of 300 mg allopurinol and 60 mg benzbromarone daily. The sum of the excretion rates of the two pyrazolopyrimidines in the 24-hour urine represents 80.9% and 77.1%, respectively of the daily dose of allopurinol given alone or in combination with benzbromarone. As expected, the hypouricaemic effect of the combined therapy turned out to be stronger than that observed after monotherapy with allopurinol, due to the uricosuric component of benzbromarone. The difference was found to be highly significant.
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use* / Q000652:urine; D001553:Benzbromarone / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D004359:Drug Therapy, Combination; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006073:Gout / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D010117:Oxypurinol / Q000652:urine*; D011743:Pyrimidines / Q000652:urine*; D014527:Uric Acid / Q000652:urine
D001572:Benzofurans; D011743:Pyrimidines; D014527:Uric Acid; D001553:Benzbromarone; D000493:Allopurinol; D003404:Creatinine; D010117:Oxypurinol